On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
ORGANIZATION
FPMAJ Confirms Regulatory Compliance Actions Completed for All Generic Drug Discrepancies
The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) said on July 1 that all necessary regulatory procedures have been completed for generic products flagged with manufacturing or testing discrepancies during last year’s industrywide self-inspections. The inspections stemmed from an…
To read the full story
Related Article
- FPMAJ Reports Detailed Results of Blanket Self-Inspections for Generic Firms
January 29, 2025
- Japan Requests Self-Inspections for All Generic Firms; Report Due by October-End
April 9, 2024
- Industry Explains Scheme to Deal with New Self-Inspection Asked for All Generic Makers
March 19, 2024
- MHLW to Ask All Generic Makers in Japan to Execute Self-Inspections
March 4, 2024
ORGANIZATION
- JMA Renews Backing for Hanako Jimi in 2028 Upper House Race
November 11, 2026
- Rethink Labor Cost Calculations in Drug Pricing: Pharma Labor Group
November 5, 2026
- Medipal’s Choufuku Takes Over as JPWA Vice Chair
November 4, 2026
- Enhertu, Dupixent Win 2026 International Prix Galien Biotechnology Award
November 2, 2026
- Pharma Trade Groups Flag Potential Leak of 30,000 Email Addresses
November 2, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…